1
|
Bu J, Jeong WJ, Jafari R, Kubiatowicz LJ, Nair A, Poellmann MJ, Hong RS, Liu EW, Owen RH, Rawding PA, Hopkins CM, Kim D, George DJ, Armstrong AJ, Král P, Wang AZ, Bruce J, Zhang T, Kimple RJ, Hong S. Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. Biosens Bioelectron 2022; 213:114445. [PMID: 35679646 DOI: 10.1016/j.bios.2022.114445] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 05/13/2022] [Accepted: 05/30/2022] [Indexed: 11/02/2022]
Abstract
Despite its high potential, PD-L1 expressed by tumors has not been successfully utilized as a biomarker for estimating treatment responses to immunotherapy. Circulating tumor cells (CTCs) and tumor-derived exosomes that express PD-L1 can potentially be used as biomarkers; however, currently available assays lack clinically significant sensitivity and specificity. Here, a novel peptide-based capture surface is developed to effectively isolate PD-L1-expressing CTCs and exosomes from human blood. For the effective targeting of PD-L1, this study integrates peptide engineering strategies to enhance the binding strength and specificity of a β-hairpin peptide derived from PD-1 (pPD-1). Specifically, this study examines the effect of poly(ethylene glycol) spacers, the secondary peptide structure, and modification of peptide sequences (e.g., removal of biologically redundant amino acid residues) on capture efficiency. The optimized pPD-1 configuration captures PD-L1-expressing tumor cells and tumor-derived exosomes with 1.5-fold (p = 0.016) and 1.2-fold (p = 0.037) higher efficiencies, respectively, than their whole antibody counterpart (aPD-L1). This enhanced efficiency is translated into more clinically significant detection of CTCs (1.9-fold increase; p = 0.035) and exosomes (1.5-fold increase; p = 0.047) from patients' baseline samples, demonstrating stronger correlation with patients' treatment responses. Additionally, we confirmed that the clinical accuracy of our system can be further improved by co-analyzing the two biomarkers (bimodal CTC/exosome analysis). These data demonstrate that pPD-1-based capture is a promising approach for capturing PD-L1-expressing CTCs and exosomes, which can be used as a reliable biomarker for cancer immunotherapy.
Collapse
Affiliation(s)
- Jiyoon Bu
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA; Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon, 22212, Republic of Korea
| | - Woo-Jin Jeong
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA; Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon, 22212, Republic of Korea
| | - Roya Jafari
- Department of Chemistry, University of Illinois at Chicago, 845 W Taylor St, Chicago, IL, 60607, USA
| | - Luke J Kubiatowicz
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Ashita Nair
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Michael J Poellmann
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Rachel S Hong
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Elizabeth W Liu
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Randall H Owen
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Piper A Rawding
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Caroline M Hopkins
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - DaWon Kim
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA
| | - Daniel J George
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, 10 Bryan Searle Drive, Durham, NC, 27710, USA; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, 20 Duke Medicine Cir, Durham, NC, 27710, USA
| | - Andrew J Armstrong
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, 10 Bryan Searle Drive, Durham, NC, 27710, USA; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, 20 Duke Medicine Cir, Durham, NC, 27710, USA
| | - Petr Král
- Department of Chemistry, University of Illinois at Chicago, 845 W Taylor St, Chicago, IL, 60607, USA; Department of Physics, Department of Pharmaceutical Sciences, University of Illinois at Chicago, 845 W Taylar St, Chicage, IL, 60607, USA
| | - Andrew Z Wang
- Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Department of Radiation Oncology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Justine Bruce
- Department of Human Oncology, University of Wisconsin-Madison, Madison, 600 Highland Ave, WI, 53792, USA; UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, 600 Highland Ave, WI, 53792, USA
| | - Tian Zhang
- Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, 10 Bryan Searle Drive, Durham, NC, 27710, USA; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, 20 Duke Medicine Cir, Durham, NC, 27710, USA; Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Randall J Kimple
- Department of Human Oncology, University of Wisconsin-Madison, Madison, 600 Highland Ave, WI, 53792, USA; UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, 600 Highland Ave, WI, 53792, USA
| | - Seungpyo Hong
- Pharmaceutical Sciences Division and Wisconsin Center for NanoBioSystems (WisCNano), School of Pharmacy, University of Wisconsin - Madison, 777 Highland Ave, Madison, WI, 53705, USA; UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, 600 Highland Ave, WI, 53792, USA; Department of Biomedical Engineering, The University of Wisconsin-Madison, 1550 Engineering Dr., Madison, WI, 53705, USA; Yonsei Frontier Lab, Department of Pharmacy, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
| |
Collapse
|
2
|
Lu L, Raj S, Arizmendi N, Ding J, Eitzen G, Kwan P, Kulka M, Unsworth LD. Identification of short peptide sequences that activate human mast cells via Mas-related G-protein coupled receptor member X2. Acta Biomater 2021; 136:159-169. [PMID: 34530142 DOI: 10.1016/j.actbio.2021.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 08/24/2021] [Accepted: 09/07/2021] [Indexed: 11/19/2022]
Abstract
Peptide based therapeutics are desirable owing to their high biological specificity. However, a number of these fail in clinical testing due to an adverse inflammatory response. Mast cells play a key role in directing the host response to drugs and related products. Although the role of FcεRI receptor is well known, Mas-related G-protein coupled receptor X2 (MRGPRX2) binding of endogenous peptides, and drugs will activate mast cells independent of FcεRI. Identifying peptides that activate mast cells through MRGPRX2, and their respective activation potency, can be used to reduce the failure rate of peptide therapeutics at clinical trial. Moreover, it will allow for peptide design where mast cell activation is actually desired. It was found that FRKKW and WNKWAL are two motifs that activate human LAD2 cells similar to PAMP-12 controls. Peptide activators of MRGPRX2 could be reduced to Xa-(Y)(n ≥ 3)-Xb where: Xa is an aromatic residue; Xb is a hydrophobic residue; and Y is a minimum 3 residue long sequence, containing a minimum of one positively charged residue with the remainder being uncharged residues. Artificial peptides WKKKW and FKKKF were constructed to test this structural functionality and were similar to PAMP-12 controls. Peptides with different activation potentials were found where FRKKW = WKKKW = FKKKF > PAMP-12 = WNKWAL > YKKKY > FRKKANKWALSR = FRKKWNKAALSR > KWKWK > FRKK = WNKWA > KYKYK > NKWALSR = YKKY = WNK. These sequences should be considered when designing peptide-based therapeutics. STATEMENT OF SIGNIFICANCE: Mast cells release immune regulating molecules upon activation that direct host's immune response. MRGPRX2 receptor provides an alternate pathway for mast cell activation that is independent of FcεRI receptor. It is thought that mast cell activation through MRGPRX2 plays a critical role in high failure rates of drugs in clinical trials. Identifying peptide sequences that activate mast cells through MRGPRX2 can serve two important purposes, namely, sequences to avoid when designing peptide therapeutics, and artificial peptides with different activation potentials for mast cells. Herein, we have identified a general amino acid sequence that induces mast cell activation through MRGPRX2. Furthermore, by modulating the identified sequence, artificial peptides have been designed which activate mast cells by varying degrees for therapeutic applications.
Collapse
Affiliation(s)
- Lei Lu
- Department of Chemical and Materials Engineering, Donadeo Innovation Center for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB T6G1H9, Canada; School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan 610031, China
| | - Shammy Raj
- Department of Chemical and Materials Engineering, Donadeo Innovation Center for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB T6G1H9, Canada
| | - Narcy Arizmendi
- Nanotechnology Research Council (Canada), 11421 Saskatchewan Drive NW, Edmonton, AB T6G2M9, Canada
| | - Jie Ding
- Wound Healing Research Group, Division of Plastic and Reconstructive Surgery, University of Alberta, 2D2.28 WMC, 8440-112 Street, Edmonton, AB T6G2B7, Canada
| | - Gary Eitzen
- Department of Cell Biology, MSB 5-14, University of Alberta, Edmonton, AB T6G2H7, Canada
| | - Peter Kwan
- Wound Healing Research Group, Division of Plastic and Reconstructive Surgery, University of Alberta, 2D2.28 WMC, 8440-112 Street, Edmonton, AB T6G2B7, Canada
| | - Marianna Kulka
- Nanotechnology Research Council (Canada), 11421 Saskatchewan Drive NW, Edmonton, AB T6G2M9, Canada; Department of Medical Microbiology and Immunology, University of Alberta, 6-020 Katz Group Center, Edmonton, AB T6G2E1, Canada.
| | - Larry D Unsworth
- Department of Chemical and Materials Engineering, Donadeo Innovation Center for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB T6G1H9, Canada.
| |
Collapse
|
3
|
Fritz ZR, Schloss RS, Yarmush ML, Williams LJ. HSymM-guided engineering of the immunodominant p53 transactivation domain putative peptide antigen for improved binding to its anti-p53 monoclonal antibody. Bioorg Med Chem Lett 2021; 51:128341. [PMID: 34454062 PMCID: PMC8526406 DOI: 10.1016/j.bmcl.2021.128341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 08/17/2021] [Accepted: 08/22/2021] [Indexed: 02/07/2023]
Abstract
A novel engineering strategy to improve autoantibody detection with peptide fragments derived from the parent antigen is presented. The model system studied was the binding of the putative p53 TAD peptide antigen (residues 46-55) to its cognate anti-p53 antibody, ab28. Each engineered peptide contained the full decapeptide epitope and differed only in the flanking regions. Since minimal structural information was available to guide the design, a simple epitope:paratope binding model was applied. The Hidden Symmetry Model, which we recently reported, was used to guide peptide design and estimate per-residue contributions to interaction free energy as a function of added C- and N-terminal flanking peptides. Twenty-four peptide constructs were designed, synthesized, and assessed for binding affinity to ab28 by surface plasmon resonance, and a subset of these peptides were evaluated in a simulated immunoassay for limit of detection. Many peptides exhibited over 200-fold enhancements in binding affinity and improved limits of detection. The epitope was reevaluated and is proposed to be the undecapeptide corresponding to residues 45-55. HSymM calculated binding free energy and experimental data were found to be in good agreement (R2 > 0.75).
Collapse
Affiliation(s)
- Zachary R Fritz
- Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, United States
| | - Rene S Schloss
- Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, United States
| | - Martin L Yarmush
- Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, United States
| | - Lawrence J Williams
- Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854, United States.
| |
Collapse
|
4
|
Sarikaya R, Song L, Yuca E, Xie SX, Boone K, Misra A, Spencer P, Tamerler C. Bioinspired multifunctional adhesive system for next generation bio-additively designed dental restorations. J Mech Behav Biomed Mater 2021; 113:104135. [PMID: 33160267 PMCID: PMC8101502 DOI: 10.1016/j.jmbbm.2020.104135] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 07/17/2020] [Accepted: 10/07/2020] [Indexed: 12/16/2022]
Abstract
Resin-based composite has overtaken dental amalgam as the most popular material for the repair of lost or damaged tooth structure. In spite of the popularity, the average composite lifetime is about half that of amalgam restorations. The leading cause of composite-restoration failure is decay at the margin where the adhesive is applied. The adhesive is intended to seal the composite/tooth interface, but the adhesive seal to dentin is fragile and readily degraded by acids, enzymes and other oral fluids. The inherent weakness of this material system is attributable to several factors including the lack of antimicrobial properties, remineralization capabilities and durable mechanical performance - elements that are central to the integrity of the adhesive/dentin (a/d) interfacial seal. Our approach to this problem offers a transition from a hybrid to a biohybrid structure. Discrete peptides are tethered to polymers to provide multi-bio-functional adhesive formulations that simultaneously achieve antimicrobial and remineralization properties. The bio-additive materials design combines several functional properties with the goal of providing an adhesive that will serve as a durable barrier to recurrent decay at the composite/tooth interface. This article provides an overview of our multi-faceted approach which uses peptides tethered to polymers and new polymer chemistries to achieve the next generation adhesive system - an adhesive that provides antimicrobial properties, repair of defective dentin and enhanced mechanical performance.
Collapse
Affiliation(s)
- Rizacan Sarikaya
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Department of Mechanical Engineering, University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA
| | - Linyong Song
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA
| | - Esra Yuca
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Department of Molecular Biology and Genetics, Yildiz Technical University, Istanbul, 34210, Turkey
| | - Sheng-Xue Xie
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA
| | - Kyle Boone
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Bioengineering Program, University of Kansas, 1530 W. 15th St, University of Kansas (KU), Lawrence, KS, 66045, USA
| | - Anil Misra
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Civil, Environmental and Architectural Engineering Department, University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA
| | - Paulette Spencer
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Department of Mechanical Engineering, University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Bioengineering Program, University of Kansas, 1530 W. 15th St, University of Kansas (KU), Lawrence, KS, 66045, USA
| | - Candan Tamerler
- Institute for Bioengineering Research (IBER), University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Department of Mechanical Engineering, University of Kansas (KU), 1530 W. 15th St, Lawrence, KS, 66045, USA; Bioengineering Program, University of Kansas, 1530 W. 15th St, University of Kansas (KU), Lawrence, KS, 66045, USA.
| |
Collapse
|
5
|
Urello M, Hsu WH, Christie RJ. Peptides as a material platform for gene delivery: Emerging concepts and converging technologies. Acta Biomater 2020; 117:40-59. [PMID: 32966922 DOI: 10.1016/j.actbio.2020.09.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 08/27/2020] [Accepted: 09/16/2020] [Indexed: 02/06/2023]
Abstract
Successful gene therapies rely on methods that safely introduce DNA into target cells and enable subsequent expression of proteins. To that end, peptides are an attractive materials platform for DNA delivery, facilitating condensation into nanoparticles, delivery into cells, and subcellular release to enable protein expression. Peptides are programmable materials that can be designed to address biocompatibility, stability, and subcellular barriers that limit efficiency of non-viral gene delivery systems. This review focuses on fundamental structure-function relationships regarding peptide design and their impact on nanoparticle physical properties, biologic activity, and biocompatibility. Recent peptide technologies utilize multi-dimensional structures, non-natural chemistries, and combinations of peptides with lipids to achieve desired properties and efficient transfection. Advances in DNA cargo design are also presented to highlight further opportunities for peptide-based gene delivery. Modern DNA designs enable prolonged expression compared to traditional plasmids, providing an additional component that can be synergized with peptide carriers for improved transfection. Peptide transfection systems are poised to become a flexible and efficient platform incorporating new chemistries, functionalities, and improved DNA cargos to usher in a new era of gene therapy.
Collapse
|
6
|
He Y, Li M, Tong G, Meng Y, Hao S, Hu S, Yan W, Yang D. hPTH(3-34)(29-34) selectively activated PKC and mimicked osteoanabolic effects of hPTH(1-34). Bone 2020; 135:115326. [PMID: 32200023 DOI: 10.1016/j.bone.2020.115326] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 03/15/2020] [Accepted: 03/17/2020] [Indexed: 01/07/2023]
Abstract
Teriparatide (hPTH(1-34)) exhibits both osteoanabolic and osteocatabolic effects. We generated a novel PTH analog by duplicating the PTH(29-34) domain to hPTH(3-34) (named MY-1), which was identified to activate PKC but not PLC and cAMP/PKA signaling. It increased osteo-differentiation but did not affect osteoclastogenesis and RANKL expression in primary osteoblasts or bone marrow cells. MY-1 and hPTH(1-34) increased the synthesis and decreased the degradation οf β-catenin protein in osteoblasts, while PKC inhibitor blunted such effects. In vivo results indicated that intermittent MY-1 and hPTH(1-34) prevented bone loss in ovariectomized mice, and that MY-1 infusion increased bone volume in normal mice. Histological analysis observed more osteoclasts surrounding the cancellous bone surface in hPTH(1-34), but not MY-1 treated mice. We conclude that MY-1 mimicked the osteoanabolic but not the osteocatabolic effects of hPTH(1-34), which is related to PKC and β-catenin signaling. Such anabolic-only analog provides a new strategy to study PTH's versatile functions and design new medicines to treat osteoporosis and bone defects.
Collapse
Affiliation(s)
- Youhua He
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Minghan Li
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Guojun Tong
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Yue Meng
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Song Hao
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Shaoyu Hu
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Wenjuan Yan
- Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
| | - Dehong Yang
- Department of Orthopedics-Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
| |
Collapse
|
7
|
Harris KS, Poon S, Quimbar P, Anderson MA. In Vitro and In Planta Cyclization of Target Peptides Using an Asparaginyl Endopeptidase from Oldenlandia affinis. Methods Mol Biol 2019; 2012:211-35. [PMID: 31161511 DOI: 10.1007/978-1-4939-9546-2_12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Cyclization of the peptide backbone by connecting the N- and C-terminus can endow target peptides with favorable properties, such as increased stability or potential oral bioavailability. However, there are few tools available for carrying out this modification. Asparaginyl endopeptidases (AEPs) are a class of enzymes that typically work as proteases, but a subset is highly efficient at cyclization of the peptide backbone. In this chapter we describe how to utilize a cyclizing AEP (OaAEP1b) to produce backbone-cyclized peptides both in planta and in vitro. Using the in planta method, OaAEP1b and the target precursor peptide are coexpressed in the leaves of the model plant Nicotiana benthamiana, and cyclization of the target peptide occurs in planta. Using the in vitro method, purified recombinant OaAEP1b produced in bacteria is used to cyclize the target precursor peptide in vitro.
Collapse
|
8
|
Foight GW, Chen TS, Richman D, Keating AE. Enriching Peptide Libraries for Binding Affinity and Specificity Through Computationally Directed Library Design. Methods Mol Biol 2018; 1561:213-232. [PMID: 28236241 DOI: 10.1007/978-1-4939-6798-8_13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Peptide reagents with high affinity or specificity for their target protein interaction partner are of utility for many important applications. Optimization of peptide binding by screening large libraries is a proven and powerful approach. Libraries designed to be enriched in peptide sequences that are predicted to have desired affinity or specificity characteristics are more likely to yield success than random mutagenesis. We present a library optimization method in which the choice of amino acids to encode at each peptide position can be guided by available experimental data or structure-based predictions. We discuss how to use analysis of predicted library performance to inform rounds of library design. Finally, we include protocols for more complex library design procedures that consider the chemical diversity of the amino acids at each peptide position and optimize a library score based on a user-specified input model.
Collapse
Affiliation(s)
- Glenna Wink Foight
- Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg., 68-622, Cambridge, MA, 02139, USA
- Department of Chemistry, University of Washington, Seattle, WA, 98195, USA
| | - T Scott Chen
- Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg., 68-622, Cambridge, MA, 02139, USA
- Google Inc., Mountain View, CA, 94043, USA
| | - Daniel Richman
- Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg., 68-622, Cambridge, MA, 02139, USA
| | - Amy E Keating
- Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg., 68-622, Cambridge, MA, 02139, USA.
- Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg., 68-622, Cambridge, MA, 02139, USA.
| |
Collapse
|
9
|
Abstract
Peptides with the cystine-knot architecture, often termed knottins, are promising scaffolds for biomolecular engineering. These unique molecules combine diverse bioactivities with excellent structural, thermal, and proteolytical stability. Being different in the composition and structure of their amino acid backbone, knottins share the same core element, namely cystine knot, which is built by six cysteine residues forming three disulfides upon oxidative folding. This motif ensures a notably rigid framework that highly tolerates both rational and combinatorial changes in the primary structure. Being accessible through recombinant production and total chemical synthesis, cystine-knot miniproteins can be endowed with novel bioactivities by variation of surface-exposed loops and incorporation of non-natural elements within their non-conserved regions towards the generation of tailor-made peptidic compounds. In this chapter the topology of cystine-knot peptides, their synthesis and applications for diagnostics and therapy is discussed.
Collapse
|
10
|
Migliaccio N, Palmieri C, Ruggiero I, Fiume G, Martucci NM, Scala I, Quinto I, Scala G, Lamberti A, Arcari P. B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy. Cancer Cell Int 2015; 15:50. [PMID: 25983658 PMCID: PMC4433068 DOI: 10.1186/s12935-015-0202-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Accepted: 04/28/2015] [Indexed: 02/02/2023] Open
Abstract
Background Despite the clinical response of conventional anticancer therapy, including chemotherapeutic treatments, radiation therapy and corticosteroids, tumorigenic B-cell lymphomas show an incomplete response to clinical practices that result in a minimal residual disease (MRD) where few residual neoplastic cells undetected in vivo, replenish the cancer cell reservoir. This scenario, which is also shared with other cancer diseases, requires the development of strategies to advance in novel, selective targeting toward the tumorigenic cells that survive to the anticancer agents. Methods Here, we have taken advantage of the therapeutic properties of an idiotype specific peptide (pA20-36) that bind specifically to murine B-lymphoma cells in the setting of an anti cancer strategy, based on the selected delivery of electrostatic-based complex, peptide-siRNA. To this end, two engineered, arginine rich, peptides that included the pA20-36 targeting sequence were designed to bind fluorescent-labelled siRNA. One peptide presented 9 Arg at the C-terminal of pA20-36 whereas the other included 5 Arg at the N- and C-terminus, respectively. Results Compared to the control and random peptide-siRNA complexes, both pA20-36-siRNA complexes were endowed with the selective delivering of fluorescent-labelled siRNA toward the A20 murine B-cell lymphoma, as evaluated by cytofluorimetry and confocal microscopy, whereas fluorescent-labelled siRNA alone was not internalized in the selected cells. Compared to peptide controls, the use of the modified pA20-36 peptides complexed with siRNA anti-GAPDH and anti-Bcl2 showed a down-regulation in the expression levels of the corresponding genes. Conclusions Peptide-siRNA complex can be suitable tool for both selective peptide-driven cell targeting and gene silencing. In this setting, the improvement of this strategy is expected to provide a safe and non-invasive approach for the delivery of therapeutic molecules.
Collapse
Affiliation(s)
- Nunzia Migliaccio
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Camillo Palmieri
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Immacolata Ruggiero
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Nicola M Martucci
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Iris Scala
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Giuseppe Scala
- Department of Experimental and Clinical Medicine, University of Magna Graecia, Viale Europa, I-88100 Germaneto, Catanzaro, Italy
| | - Annalisa Lamberti
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy
| | - Paolo Arcari
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, I-80131 Naples, Italy ; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini, I-80131 Naples, Italy
| |
Collapse
|